159 related articles for article (PubMed ID: 1759815)
1. Microculture screening assay for primary in vitro evaluation of drugs against Pneumocystis carinii.
Comley JC; Mullin RJ; Wolfe LA; Hanlon MH; Ferone R
Antimicrob Agents Chemother; 1991 Oct; 35(10):1965-74. PubMed ID: 1759815
[TBL] [Abstract][Full Text] [Related]
2. A radiometric method for objectively screening large numbers of compounds against Pneumocystis carinii in vitro.
Comley JC; Mullin RJ; Wolfe LA; Hanlon MH; Ferone R
J Protozool; 1991; 38(6):144S-146S. PubMed ID: 1818144
[TBL] [Abstract][Full Text] [Related]
3. Characterization of de novo folate synthesis in Pneumocystis carinii and Toxoplasma gondii: potential for screening therapeutic agents.
Kovacs JA; Allegra CJ; Beaver J; Boarman D; Lewis M; Parrillo JE; Chabner B; Masur H
J Infect Dis; 1989 Aug; 160(2):312-20. PubMed ID: 2527275
[TBL] [Abstract][Full Text] [Related]
4. Pteroylpolyglutamate synthesis by lung- and culture-derived Pneumocystis carinii.
Hong YL; Bartlett MS; Queener S; Smith JW; Shaw M; Meshnick SR
FEMS Microbiol Lett; 1995 Dec; 134(2-3):251-4. PubMed ID: 8586276
[TBL] [Abstract][Full Text] [Related]
5. Development and characterization of a rapid screening assay for identifying antipneumocystis agents.
Martinez A; Kovacs JA
Antimicrob Agents Chemother; 1993 Aug; 37(8):1674-8. PubMed ID: 8215282
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Pneumocystis carinii dihydropteroate synthetase by para-acetamidobenzoic acid: possible mechanism of action of isoprinosine in human immunodeficiency virus infection.
Kovacs JA; Powell F; Voeller D; Allegra CJ
Antimicrob Agents Chemother; 1993 Jun; 37(6):1227-31. PubMed ID: 7687120
[TBL] [Abstract][Full Text] [Related]
7. Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations.
Piper JR; Johnson CA; Krauth CA; Carter RL; Hosmer CA; Queener SF; Borotz SE; Pfefferkorn ER
J Med Chem; 1996 Mar; 39(6):1271-80. PubMed ID: 8632434
[TBL] [Abstract][Full Text] [Related]
8. Polyamine metabolism in Pneumocystis carinii.
Lipschik GY; Masur H; Kovacs JA
J Infect Dis; 1991 May; 163(5):1121-7. PubMed ID: 2019760
[TBL] [Abstract][Full Text] [Related]
9. Growth and metabolism of Pneumocystis carinii in axenic culture.
Cushion MT; Ebbets D
J Clin Microbiol; 1990 Jun; 28(6):1385-94. PubMed ID: 2380365
[TBL] [Abstract][Full Text] [Related]
10. Pneumocystis carinii dihydrofolate reductase used to screen potential antipneumocystis drugs.
Broughton MC; Queener SF
Antimicrob Agents Chemother; 1991 Jul; 35(7):1348-55. PubMed ID: 1929292
[TBL] [Abstract][Full Text] [Related]
11. Metabolic and synthetic activities of Pneumocystis carinii in vitro.
Pesanti EL; Cox C
Infect Immun; 1981 Dec; 34(3):908-14. PubMed ID: 6174453
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of recombinant Pneumocystis carinii dihydropteroate synthetase by sulfa drugs.
Hong YL; Hossler PA; Calhoun DH; Meshnick SR
Antimicrob Agents Chemother; 1995 Aug; 39(8):1756-63. PubMed ID: 7486915
[TBL] [Abstract][Full Text] [Related]
13. Effects of atovaquone and diospyrin-based drugs on the cellular ATP of Pneumocystis carinii f. sp. carinii.
Cushion MT; Collins M; Hazra B; Kaneshiro ES
Antimicrob Agents Chemother; 2000 Mar; 44(3):713-9. PubMed ID: 10681344
[TBL] [Abstract][Full Text] [Related]
14. Effects of atovaquone and diospyrin-based drugs on ubiquinone biosynthesis in Pneumocystis carinii organisms.
Kaneshiro ES; Sul D; Hazra B
Antimicrob Agents Chemother; 2000 Jan; 44(1):14-8. PubMed ID: 10602716
[TBL] [Abstract][Full Text] [Related]
15. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia.
Kovacs JA; Gill VJ; Meshnick S; Masur H
JAMA; 2001 Nov; 286(19):2450-60. PubMed ID: 11712941
[TBL] [Abstract][Full Text] [Related]
16. Occurrence of specific sterols in Pneumocystis carinii.
Florin-Christensen M; Florin-Christensen J; Wu YP; Zhou L; Gupta A; Rudney H; Kaneshiro ES
Biochem Biophys Res Commun; 1994 Jan; 198(1):236-42. PubMed ID: 8292026
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of potent inhibitors of dihydrofolate reductase in a culture model for growth of Pneumocystis carinii.
Bartlett MS; Shaw M; Navaran P; Smith JW; Queener SF
Antimicrob Agents Chemother; 1995 Nov; 39(11):2436-41. PubMed ID: 8585722
[TBL] [Abstract][Full Text] [Related]
18. Biological profile and response to anti-pneumocystis agents of Pneumocystis carinii in cell culture.
Pifer LL; Pifer DD; Woods DR
Antimicrob Agents Chemother; 1983 Nov; 24(5):674-8. PubMed ID: 6607029
[TBL] [Abstract][Full Text] [Related]
19. Dihydropteroate synthase mutations in Pneumocystis jiroveci can affect sulfamethoxazole resistance in a Saccharomyces cerevisiae model.
Iliades P; Meshnick SR; Macreadie IG
Antimicrob Agents Chemother; 2004 Jul; 48(7):2617-23. PubMed ID: 15215118
[TBL] [Abstract][Full Text] [Related]
20. In vitro pharmacodynamic parameters of sordarin derivatives in comparison with those of marketed compounds against Pneumocystis carinii isolated from rats.
Aviles P; Aliouat EM; Martinez A; Dei-Cas E; Herreros E; Dujardin L; Gargallo-Viola D
Antimicrob Agents Chemother; 2000 May; 44(5):1284-90. PubMed ID: 10770763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
